drugset / Trial / NCT02980133

Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler

NCT02980133

Phase 3 Completed 841 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is to evaluate the safety and efficacy of fluticasone propionate and fluticasone propionate salmeterol in pediatric participants with a documented history of persistent asthma.

Timeline

Start
2016-12-28
Primary completion
2019-04-07
Completion
2019-04-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified 25 ug Inhaled
Subject Fluticasone propionate Other / unclassified 50 ug Inhaled
Subject Salmeterol Other / unclassified 12.5 ug Inhaled

Indications